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ABSTRACT Members of the structurally diverse
class of drugs known as nonsteroidal anti-inflam-
matory drugs (NSAIDs) have the ability to prevent
or reduce the occurrence of colorectal, certain
other gastrointestinal, and perhaps other cancers.
The antic arcinogenic property of NSAIDs has been
shown in epidemiological studies with humans and
in experimental carcinogenesis studies with anfinals.
In addition, clinical studies of the human disease fa-
milial adenomatous polyposis have demonstrated
the efficacy of NSAIDs in mediating regression of
colorectal adenomas. The mechanism of the anti-
carcinogenic effect of these drugs is not known, but
most hypotheses have involved the common prop-
erty of the NSAIDs to inhibit prostaglandin synthase
(PHS) enzymes and thereby cause a subsequent re-
duction in levels of prostaglandins (PG) in tissue.
Recent reports have questioned the role of PHS in-
hibition in the anticarcinogenic activity of NSAIDs
by showing that some NSAID-related compounds
that are not PHS inhibitors can induce the same an-
ticarcinogenic changes in cell cycle and apoptotic
response as the PHS inhibitors. In this review we will
examine the evidence that NSAIDs are anticarcino-
genic, the evidence supporting PHS as the target of
NSAIDs, and the evidence for and against inhibition
of PG synthesis as the mechanism of cancer preven-
tion by NSAIDs. -Levy, G. N. Prostaglandin H syn-
thases, nonsteroidal anti-inflammatory drugs, and
colon cancer. FASEBJ. 11, 234-247 (1997)
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NSAIDs REDUCE THE RISK OF
COLORECTAL CANCER IN HUMANS
Epidemiologic observations of a reduction in the incidence
of colon cancer in regular users of aspirin was reported in
1988 (1). This Australian study reported a 40-50% re-
duction in colon cancer incidence among regular aspirin
users. Most subsequent studies have reported similar find-
ings (2-7). An exception to this trend is a study of elderly
Californians that showed a moderate increase in colon can-
cer among aspirin users (8).
The largest study of nonsteroidal anti-inflammatory
drugs (NSAIDs)2 and colon cancer involves more than
600,000 individuals who were followed for fatal colon can-
cer and aspirin use (3). As in the other epidemiologic stud-
ies, quantitation of dose was imprecise but was estimated
by ranking use into the categories of none, less than once,
1-15, and 16 or more times per month. The rate of colon
cancer death was inversely related to aspirin use in a dose-
dependent manner. The relative risk of fatal colon cancer
for users of aspirin at 16 or more times per month was 0.60
for men and 0.58 for women. The relative risks did not
change substantially after exclusion of individuals with
preexisting disease at entry or after adjustment for other
potential risk factors (3). In contrast to the results for as-
pirin use, no association of change in fatal colon cancer
risk with acetaminophen use was found. Also in contrast
to NSAIDs, steroidal anti-inflammatory drugs, which are
known to inhibit expression of PHS-2 (9), did not decrease
the risk of colon adenomas or adenocarcinomas (10).
Further follow-up and analysis of the population in this
large study demonstrated a decreased death rate from can-
cers of the esophagus, stomach, and rectum in addition to
that of colon among aspirin users (11). The reduction in
risk of fatal digestive tract cancer among aspirin users was
dose-dependent and the trend was strongest for persons
who had used aspirin for 10 or more years. No consistent
dose-response relationships were found between aspirin
use and cancers outside the digestive tract.
NSAIDs ARE ANTICARCINOGENIC IN
ANIMALS
In a wide variety of experimental systems NSAIDs includ-
ing indomethacin, phenylbutazone, aspirin, piroxicam, ke-
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toprofen, and sulindac have been shown to inhibit
chemically induced tumors. A few examples are presented
here. Esophageal tumors in mice treated with N-nitroso-
diethylamine were reduced by indomethacin administered
either with the carcinogen or 4 months after exposure (12).
Pancreatic tumors induced by N-nitrosobis(2-oxopro-
pyl)amine were reduced in hamsters receiving the pros-
taglandin synthase inhibitors indomethacin,
phenylbutazone, or aspirin beginning 5 wk after initiation
of carcinogenesis (13). FANFT (N-(4-(5-nitro-2-furyl)-2-
thiazolyl)-formamide), a potent urinary bladder carcinogen
in the rat, is activated in vitro by PHS. Aspirin treatment
of rats exposed to FANFT for 12 wk showed a major re-
duction in the incidence of bladder cancer compared to
FANFT-exposed but untreated rats (14). The effect of two
NSAIDs, indomethacin and carprofen, on the enhance-
ment of 7,12-dimethylbenz(a)anthracene-induced mam-
mary carcinogenesis by dietary linoleate in rats was
compared. Indomethacin had a marked inhibitory effect
on the rats fed diets high in linoleate, but carprofen was
not inhibitory at any fat level. Both NSAIDs reduced the
level of PGE2, demonstrating that the inhibition of exper-
imental mammary tumors in rats by these drugs does not
correlate with decreases in PG levels (15). Thus, in this
experimental system, reduction of PG levels and tumor
inhibition are separable processes.
Differences between species in the effectiveness of var-
ious NSAIDs as chemopreventive agents have been shown
to occur. N-butyl-N-(4-hydroxybutyl)nitrosamine (OH-
BBN) induces rapidly growing and highly invasive tran-
sitional cell carcinomas of the bladder in male B6D2F1
mice. Sulindac and ketoprofen, hut not aspirin, signifi-
cantly reduced OH-BBN-induced bladder tumors in these
mice as illustrated in Fig. 1 (16). In contrast, aspirin is
effective in preventing OH-BBN-induced bladder tumors
in rats, where the tumors resulting from OH-BBN treat-
ment are relatively slow-growing (17).
The most frequently studied tissue for the effect of
NSAIDs on experimental carcinogenesis and the one with
most relevance to human epidemiologic data is the intes-
tinal tract. Pollard and Luckert (18) showed that indo-
methacin caused a 40% reduction in 1,2-dimethyihy-
drazine-induced intestinal tumors in rats. Narisawa et a!.
(19) demonstrated that rats exposed to methylnitrosourea
developed colonic tumors that could be significantly low-
ered by indomethacin. However, in rats given the carcin-
ogen and then indomethacin, cessation of treatment led to
rapid development of tumors. Thus, indomethacin treat-
ment inhibited the development of tumors but did not
reject or kill the initiated cells. The influence of indo-
methacin and meclofenamate on the development of di-
methy!hydrazine-induced tumors in rats was examined by
Metzger et al. (20). Colon cancer incidence was 56% in
the carcinogen-exposed, indomethacin-treated animals,
90% in the carcinogen-exposed, meclofenamate-treated
group, and 88% in the carcinogen-exposed, untreated con-
trols. Piroxicam was shown to inhibit azoxymethane-in-
duced colon cancer in rats in a dose-dependent manner
Figure 1. Inhibition of OH-BBN-induced bladder tumors in mice (16).
Treatments: control: ASA 800 mg/kg diet or ketoprofen 80 mg/kg or
sulindac 400 mg/kg, no OH- BBN. None: OH-BBN alone. ASA: OH-
BBN plus aspirin 400 or 800 ing/kg diet. Keto: OH-BBN plus ketopro-
fen 40 or 80 mg/kg diet. Sul: OH-BBN plus sulindac 200 or 400 mg/
kg diet.
(21). At a dose of 150 ppm piroxicam, the incidence of
colon tumor was reduced by as much as 84% compared to
untreated controls. Sulindac was shown to have a protec-
tive effect against dimethylhydrazine-induced colonic
tumors in the mouse. Sulindac administered with the car-
cinogen caused a significant reduction in tumor incidence
and tumor burden, but sulindac administered 17 wk after
the carcinogen had no inhibitory effect, thus demonst,-at-
ing protection against initiation of tumors but no effect on
regression of established tumors in this model (22). Craven
and DeRubertis (23) examined the influence of aspirin on
dimethylhydrazine-induced colonic carcinogensis in rats.
Incidence of adenocarcinomas was reduced 69% in rats
receiving aspirin for 1 wk before and after the carcinogen.
Aspirin had no effect on tumor incidence when started 4
wk after carcinogen exposure. The aspirin dosage sup-
pressed ex vivo colonic PGE2 production by 95%. Treat-
ment with aspirin for 1 wk inhibited both basal and
arachidonate stimulated decomposition of the climethyl-
hydrazine metabolite methylazoxymethanol by colonic mu-
cosal homogenates. The authors suggest that suppression
of dimethyihydrazine-induced colonic carcinoma by as-
pirin may be altered by metabolic activation of the carcin-
ogen by cyclooxygenase-dependent cooxidation.
NSAIDs CAUSE REGRESSION OF POLYPS IN
FAP
A third line of evidence for the anticarcinogenic effect of
NSAIDs is provided by studies of familial adenomatous
polyposis (FAP), an autosoma! dominant disorder char-
acterized by the formation of hundreds of colorectal ade-
nomas and development of colorectal cancer. Several
studies have shown that the NSAID sulindac reverses co-
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lorectal polyp formation in FAP patients (24-27). Biopsy
samples, direct observation of polyps, and measurements
of levels of various enzymes and eicosanoids have been
used in attempts to determine the mechanism of sulindac’s
effect on FAP. In general, results indicate that prostaglan-
din synthase is abnormally expressed in adenomatous pol-
yps (28), eicosanoids (primarily PGEs and PGFs) are
present at higher levels in tumor than nontumor tissue
(29-31), and treatment with NSAIDs inhibits prostaglan-
din synthase and reduces tissue PG levels (32). However,
the beneficial effects of sulindac in FAP may not be seen
in sporadic colonic polyps (33).
An interesting mouse model of FAP has been developed
by Jacoby et al. (34) and by Boolbol et a!. (35) in which
C57BL/6J-Min/+ mice, a strain containing a fully pene-
trant dominant mutation in the Apc tumor suppressor gene
(leading to gastrointestinal adenomas by 110 days of age),
are used to study FAP and NSAID treatment in experi-
ments not possible with human patients. The mouse model
allowed the investigators to precisely control environmen-
tal and genetic conditions in the development of neoplasia.
In the sulindac study (35) three groups of mice were com-
pared: normal C57BL/6J (+1+) mice with the wild-type
Apc gene, the dominant mutant C57BL16J-Min/+ (Mm)
FAP mice, and the Mm mice treated with sulindac (0.5
mg/day). At 110 days of age +1+ mice had no macroscopic
intestinal tumors, Mm mice had 11.9 tumors per mouse,
and sulindac-treated Mm mice had 0.1 tumors per mouse.
Untreated Mm mice had increased expression of PHS-2
protein, increased levels of prostaglandin (PGE2) in the
intestine, and a 27-47% decrease in enterocyte apoptosis
compared to +/+ animals. Sulindac treatment of Mm an-
imals inhibited tumor formation, decreased PHS-2 and
PGE2 expression to normal levels, and restored normal
levels of apoptosis, thus demonstrating the efficacy of su-
lindac in this mouse model. In a study using piroxicam in
the Mm mouse, Jacoby et al. (34) showed a dose-depen-
dent decrease in intestinal adenomas and aberrant crypt
foci as well as a parallel decrease in serum levels of throm-
boxane B2.
ARACHIDONATE METABOLISM
Since the major known effect of the NSAIDs is inhibition
of PG synthesis, the enzyme catalyzing the committed and
rate-limiting step in production of PG has been investi-
gated as the probable common target of NSAIDs. Prosta-
glandins are products of arachidonic acid, a 20-carbon
unsaturated fatty acid found in membrane lipids. Arachi-
donic acid is metabolized, after release from membranes,
by three major pathways: cyclooxygenase, lipoxygenase,
and cytochrome P450 monooxygenase. An additional, non-
enzymatic pathway of arachidonic conversion leads to iso-
prostanes that form by free radical peroxidation of the acid
in situ in the phospholipid membrane. Formation of iso-
prostanes illustrates the formation of biologically active
autacoids as a consequence of oxidative (free radical) tis-
sue injury (36).
Each of the three major enzymatic pathways of arachi-
donate metabolism leads to a different series of com-
pounds. The cyclooxygenase pathway results in prosta-
glandins of the E2, F2, and D2 series. PG!2 (prostacyclin)
and thromboxane A2 (TXA2) are also products of the cy-
clooxygenase metabolism of arachidonic acid. The com-
mon intermediate in the synthesis of prostaglandins in
PGG2, a cyclic hydroperoxide formed by the addition of
two molecules of 02 to arachidonic acid. PGG2 is then
reduced to PGH2, an alcohol, which is further metabolized
by isomerases and synthases to the tissue PGs.
PHS, the enzyme that forms PGH2 from arachidonic
acid, has two distinct catalytic activities. It is a cycloox-
ygenase, as it cyclizes and oxygenates arachidonic acid to
form PGG2, and it is a peroxidase that reduces PGG2 to
PGH2, an alcohol. Because these two activities can be sep-
arately involved in other reactions and are inhibited by
different substances, the name prostaglandin H synthase
is probably preferable to the often-used COX (for cycloox-
ygenase) when referring to the enzyme. At least two iso-
zymes of PHS are known: PHS-1 and PHS-2. Before about
1991, work with PHS did not distinguish between the en-
zyme isoforms; however, because most of this work used
bovine or ovine seminal vesicles as the enzyme source,
and this tissue has a high content of PHS-1, PHS-1 was
most likely the form studied. PHS-2, in contrast to PHS-
1, is almost undetectable in most unstimulated tissues.
Exceptions appear to be the placenta and the brain of
newborns (37, 38), where PHS-2 is readily detectable.
PHS-2 is also present in parts of the kidney in the absence
of inflammation. Renal PHS-2 levels increase in response
to sodium restriction, which suggests that the enzyme is
important in regulating salt, volume, and blood pressure
homeostasis (39). The differences in distribution, induc-
ibility, and regulation of expression of PHS-1 and -2 have
been well covered in several recent reviews (9, 40-42).
Lipoxygenase (LOX) activity takes arachidonic acid
along a different metabolic path by inserting one molecule
of 02 to form hydroperoxyeicosatetraenoic acids (HPE-
TEs). The actual product is 5-, 12-, or 15-HPETE, de-
pending on which LOX is involved. HPETEs are next
converted to their respective hydroxyeicosatetraenoic ac-
ids (HETEs). HETEs produced via the LOX pathway are
of the S configuration. Further metabolism results in leu-
kotrienes and lipoxins, both of which exert diverse actions
in inflammation and immunity (43).
The remaining enzymatic pathway of arachidonate me-
tabolism involves enzymes of the cytochrome P450 family.
These monooxygenases insert an atom of oxygen at various
positions of arachidonic acid. P450 oxidation of arachi-
donic acid includes allylic oxidation, which is lipoxygen-
ase-like in generating 5-, 8-, 9-, 11-, 12-, and 15-HETE.
Omega hydroxylation reactions catalyzed by several P450s
oxidize C-19 and C-20 of arachidonic acid. Oxidation at
C-16, -17, and -18 has also been reported. Hydroxylation
at the omega and omega-i positions may produce HETEs
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with potent biological activities. The third major activity
of P450s on arachidonic acid is epoxidation. This reaction
produces epoxyeicosatrienoic acids (EETs) whose posi-
tional and stereochemical characteristics are controlled by
the particular P450 catalyzing the epoxidation (44). The
three pathways of arachidonate metabolism are summa-
rized in Table 1.
PROSTAGLANDIN H SYNTHASE AS THE
TARGET OF NSAIDs
Aspirin and all aspirin-like drugs including the NSAIDs
are thought to exert their anti-inflammatory, antipyretic,
and analgesic effects by inhibition of PHS (45, 46). Al-
though the mechanism of inhibition varies for different
agents, the overall effect, reduction of PG synthesis, is the
same. Aspirin alters the channel leading to the PHS active
site by irreversibly acetylating both PHS-1 (at serine 530)
and PHS-2 (at the homologous serine 516), but the effect
of this acetylation differs between isoforms. Aspirin-inhib-
ited PHS-i ceases formation of PG as its cyclooxygenase
activity is lost. The irreversible nature of the inhibition
means that PG synthesis can resume only when new PHS-
1 molecules are synthesized. In the case of platelets, even
a small dose of aspirin inhibits PG and TBX production
for a considerable period of time. Because platelets lack
the machinery for synthesis of new enzyme, the aspirin-
treated platelets are prevented from synthesizing PG for
their normal life span (8 to ii days). The result of the
acetylation of PHS-2 by aspirin is an increase in produc-
tion of i5-HETE (47-49). Investigation of the source of
15-HETE demonstrated that it is indeed the product of
PHS activity and is not produced by LOX or some other
enzyme (47). Thus, a lipoxygenase activity has been added
to the catalytic repertoire of PHS. Subsequent studies have
determined that PHS-i and -2 without aspirin treatment
both produce small amounts of iS-HETE from arachidon-
ate (47, 49) and that aspirin does not alter the production
of i5-HETE by PHS-1. The i5-HETE produced by PHS
is of the R configuration, whereas that produced by 15-
LOX is S (49, 50).
Indomethacin reacts with the active site of PHS and
induces a conformational change in the protein. Ibuprofen
inhibits PHS by substrate competition with arachidonic
acid (51). The relative inhibitory concentrations of the
NSAIDs for PHS-1 and PHS-2 have been investigated in
various cell preparations (51) and in cells transfected with
the recombinant mouse (48) or human enzymes (52). Al-
though the actual values for inhibition constants varied
depending on the experimental procedure and which pa-
rameter was being measured, the general pattern showed
that almost all compounds tested were better inhibitors
(lower IC50 values) of PHS-i than of PHS-2. Flurbiprofen,
ibuprofen, meclofenamate, and docosahexaenoic acid showed
nearly equal inhibition of the isozymes. 6-Methoxy-2-
naphthyl acetic acid, the active metabolite of nabumetone,
showed better inhibition of PHS-2 than PHS-1.
TABLE 1. Summary of arachidonate oxygenation
Enzyme Oxygen added Products Further products
PHS- Two molecules 02 PGG2 PGH2
cyclooxygenase
PHS-peroxidase - PGH2 PGs, TX
Lipoxygenases One molecule 02 HPETE HETE, Lipoxins,
Leukotrienes
P45Os One atom 0 EET Diverse
Abbreviations are defined in the text.
The interest in a specific inhibitor of PHS-2 arises from
the proposition that the ulcerogenic and other adverse
properties NSAIDs originate in the inhibition of PHS-1
whereas the therapeutically desirable effects come from
inhibition of PHS-2 (53, 54). A flurry of activity among
pharmaceutical companies has led to a number of potential
drugs as inhibitors with at least relative specificity for
PHS-2. One such compound, NS-398, was tested in vitro
as an inhibitor of PGE2 production by purified ovine PHS-
1 and PHS-2. An IC50 value of 3.8 X 106 M was found
with PHS-2 whereas PHS-1 activity was not inhibited even
at i0 M NS-398. By way of comparison, indomethacin
was a virtually equipotent inhibitor of PHS-1 and PHS-2,
with IC values of 7.4 X i0 M and 9.7 X iO M,
respectively (55). The new compound (NS-398) also pro-
duced less gastrointestinal toxicity than standard NSAIDs.
Masferrer et al. (56) used an air pouch model of inflam-
mation in rats to show that NS-398, like dexamethasone,
blocked PHS-2 expression in inflammatory cells lining the
air pouch, resulting in complete surpression of PG syn-
thesis. Neither dexamethasone nor NS-398 altered PG ex-
pression in the stomach. These results add support to the
hypothesis that PHS-1 is protective for tissues such as
gastric mucosa and that PHS-2 is the isoform expressed
during inflammation. Thus, it appears that specific inhi-
bition of PHS-2 will be a major advance in anti-inflam-
matory therapy while significantly reducing adverse
consequences of treatment.
Other specific PHS-2 inhibitors have been developed.
CGP 28238 has been tested as an inhibitor of thromboxane
synthesis by human platelets (PHS-1) and of prostacyclin
synthesis by IL-6-stimulated rat mesangial cells (PHS-2).
The ratios of IC50 values for PHS-1JPHS-2 were 0.i5 for
indomethacin, 15 for diclofenac, and 5000 for CGP 28238
(57). Another candidate PHS-2-specific inhibitor, L-
745,337, was tested by measuring PGE2 production in cul-
tured osteosarcoma cells (PHS-2) and U-937 cells
(PHS-1). The ratio of IC50PHS-1IICPHS-2 was about
500. The compound inhibited rat paw edema and hyper-
algesia, reduced the pyresis caused by endotoxin, and did
not produce gastric lesions or alter gastrointestinal integ-
rity. The compound did not lower PGE2 levels in the stom-
ach (58). Results with CGP 28238 and L-745,337 further
support the separate roles of PHS-1 and PHS-2 in gastric
protection and inflammation, respectively.
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A study of the mechanism of specific PHS-2 inhibition
by NS-398 and DuP697 (another PHS-2-specific anti-in-
flammatory) showed these compounds to be time-depen-
dent competitive inhibitors. Both drugs inhibit PHS-1 and
PHS-2 with equal potency right after mixing, but the po-
tency for PHS-2 increases with time whereas that for PHS-
1 remains low and constant. Further, PHS-i can be
reactivated by dialysis whereas PHS-2 shows no recovery
of enzyme activity after dialysis (54). The authors suggest
that the specific inhibition of PHS-2 involves an inhibitor-
induced structural transition in PEIS-2 that results in sig-
nificant and irreversible loss of activity.
Although the results obtained with specific inhibitors of
PHS-2-namely. anti-inflammatory action without gastric
ulceration-support the hypothesis that PHS-2 activity is
proinflammatory and PHS-1 activity is cytoprotective, ex-
periments with PHS-1 and PHS-2 knockout mice seem to
contradict such a simple distinction of the roles of the
isozymes. If PHS-1 is responsible for synthesizing the PGs
that protect against stomach ulceration, lack of PHS-i
should lead to ulcers. However, mice lacking the intact
PHS-I gene, and thus deficient in PHS-1 activity, do not
develop spontaneous gastric ulcers and are actually less
sensitive to gastric ulcers than normal mice after indo-
methacin treatment (59). The exclusive role of PHS-2 in
inflammation is also challenged as PHS-2 knockout mice,
shown to be devoid of PHS-2, exhibit no significant dif-
ference from normal mice in having an inflammatoiy re-
sponse to tetradecanoyl phorbol acetate or arachidonic
acid (60, 61). Although several possible explanations for
the apparently contradictory results have been offered
(62). more research is needed before the contribution of
PHS isoforms to inflammation can be fully determined.
INITIATION OF CARCINOGENESIS BY
PROSTAGLANDIN H SYNTHASES
PHS may l)e involved in the initiation of carcinogenesis
by activation of carcinogens to DNA-binding forms. Al-
though the cyclooxygenase activity of PHS is specific for
arachidonic acid and only a few other polyunsaturated
fatty acids, the peroxidase activity has a broad specificity.
In addition to the primary substrate, PGG, other hydro-
peroxides can be reduced by PHS peroxidase. A large
number of compounds can also be used as electron donors
for “cooxitlation.’ Among the classes of carcinogens that
are used as electron donors, and thereby activated by PHS,
are polycyclic aromatic hydrocarbons, aflatoxins, haloge-
nated pesticides, aromatic amines, and phenols. (63).
Numerous examples of carcinogen-DNA adducts gen-
erated by PHS have been reported (reviewed in refs 64,
65). Activation of carcinogens by PHS occurs in numerous
extrahepatic tissues and may be responsible for initiation
of cancers in those tissues (66). Carcinogen activation by
PHS can be distinguished from activation by P450 en-
zymes in vitro by the effect of specific cofactors on the
reaction. Addition of arachidonic acid will promote PHS-
catalyzed activation, whereas NADPH will increase acti-
vation by P450. Specific inhibitors are also useful in
demonstrating PHS-catalyzed activation. Indomethaci n or
aspirin will inhibit carcinogen-DNA adduct formation via
the PHS pathway (66, 67). High-peformance liquid cr0-
matography (HPLC) analysis of carcinogen-DNA adducts
formed either in vitro or in vivo can distinguish between
PHS and P450 activation. Adducts formed via PHS acti-
vation are more polar and elute earlier in reversed phase
HPLC than adducts produced by P450 activation (67, 68).
Both purified PHS-1 (67) and PHS-2 (69) were able to
activate 2-aminofluorene (AF) to a DNA binding metabo-
lite. Transfection of COS-1 cells with human PHS-2 led
to activation of AF, which could be inhibited by indo-
methacin or aspirin. Addition of phorbol myristate acetate
(PMA). a known inducer of PHS-2, to cultures of HUVEC
cells caused a threefold increase in AF-DNA adduct for-
mation and an increase in both PHS-2 mRNA and im-
munoreactive PHS-2 protein, with no effect on PHS-i
expression, supporting the role of PHS-2 in AF activation
in these stimulated cells (69). Potentially carcinogenic
compounds that pass through the colon in relatively high
concentrations include bile acids and food-derived het-
erocyclic arylamines. Knowledge of the ability of these
compounds to serve as substrates for PHS activation would
be of interest in understanding the initiation of colon can-
cers.
Another way in which PHS may be involved in initiation
of carcinogenesis is by the generation of malondialdehyde
(MDA), a direct-acting mutagen in bacterial and mam-
malian test systems that is carcinogenic in rats and forms
multiple adducts with deoxynucleotides. MDA is produced
by nonenzymatic as well as enzymatic breakdown of PGH.
Thromboxane synthase is particularly active in converting
PGH to MDA. MDA is also formed during lipid peroxi-
dation. Whereas MDA formation from PGH is inhibited
by NSAIDs. MDA formed via lipid peroxidation is not (40).
A third mechanism for the involvement of PHS in tumor
initiation involves peroxyl radicals as reactive intermedi-
ates (65). Peroxyl radicals are the most stable oxy radicals
and are able to diffuse some distance from the site of their
generation. Peroxyl radicals may he formed by PHS,
(luring lipid peroxidation, or in the reaction of polyunsat-
urated fatty acid hydroperoxides with metals or metallo-
proteins. Peroxyl radicals can epoxiclize double bonds of
procarcinogens such as benzopyrene-7,8-diol or dihy-
droxy-dihydrobenzoanthracene to produce the ultimate
carcinogens of these compounds. NSAIDs may reduce ini-
tiation via the peroxyl radical pathway by lessening the
formation of these radicals by PHS.
A relatively straightforward explanation of NSAIDs as
cancer preventive agents is possible. Since PHS isozymes
are involved in activation of carcinogens, generation of
carcinogenic malondialdehyde, and formation of carcino-
genic peroxyl radicals, inhibition of PHS activity by
NSAIDs lessens the initiation of cancers. However, this
reasoning does not adequately explain the reduction in
adenomas or existing malignant transformations that can
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occur with NSAID treatment. Effects of these drugs on
other stages of neoplasia need to be examined. These ef-
fects may include inhibition of PG synthesis, inhibition of
other reactions carried out by P1-IS, or effects independent
of PHS.
PROSTAGLANDIN H SYNTHASES AND
PROSTAGLANDINS IN TUMORS AND TUMOR
CELL LINES
Clinical evidence of the regression of polyps in FAP pa-
tients treated with sulindac (70) and the epidemiologic
demonstration of reduced risk of colon cancer by NSAID
users (3) implicate arachidonic acid metabolites in cob-
rectal cancer. The levels of prostaglandins in colon tumors
has been compared to normal colon tissue. The cycloox-
ygenase metabolites PGE2, PGF2, PGI2, TXA2, and the 5-
lipoxygenase metabolite leukotriene B4 were measured in
21 pairs of surgically excised human colon tumors and
normal colon mucosa (71). PGE2 was elevated about two-
fold (P<0.0i) in the cancer samples, whereas PGI2 was
reduced about threefold (P<0.05). No significant changes
were found in the levels of PGF2, TXA2, or leukotriene.
However, the authors also considered the ratio of PGI2 to
TXA2, as these two prostanoids have opposing actions on
platelet aggregation and vascular tone. In every paired
sample, the ratio was reduced in the cancer sample be-
tween 3.4 and and 11.5-fold (71). This shift toward proag-
gregatory thromboxane may favor tumor invasiveness,
whereas the relative decrease in prostacyclin may repre-
sent a decrease in antimetastatic activity (72).
Another investigation of PG levels in colon tumors mea-
sured PGE2 in mucosal biopsy specimens in normal-ap-
pearing mucosa from patients with adenomatous polyps
and in normal-appearing mucosa from patients with colon
cancer (73). Normal tissue from polyp patients averaged
165 pg PGE2/mg tissue; normal tissue from colon cancer
patients was not significantly different, with 147 pg PGE2/
mg tissue. However, PGE2 was significantly increased in
the adenomatous polyp to 227 pg/mg, and was even further
increased in the colon cancer to 440 pg/mg. The increase
in PGE2 level from normal to adenoma to cancer appears
parallel to the role of the adenoma as a transitional step
between normal and cancerous tissue.
Given that PGs are elevated in colonic tumors (71, 73)
and that mRNA for both PHSs are found in intestinal tis-
sue (74, 75), it is of interest to determine whether either
or both isoforms of PHS are elevated in the cancerous
colon. P115-i and -2 mRNAs were determined in human
colorectal cancers, adenomas, and normal mucosa. PHS-
2 mRNA was increased in 12 of 14 carcinomas compared
to the same patient’s normal-appearing mucosa. In three
of six pairs of adenomas and normal mucosa, the adenoma
had increased PHS-2 mRNA transcripts. Six of 14 un-
paired adenomas clearly showed PHS-2 mRNA. In con-
trast to P115-2, PHS-i mRNA levels were equivalent in
normal mucosa and cancer (28).
Similar results were obtained in a study of PHS-1 and
PHS-2 protein expression in human colon cancer. Immu-
noblot analysis was performed on protein from 25 matched
colon cancers and nontumor tissue, four premalignant pol-
yps, five control noncancerous colons, and three matched
normal and cancerous breast tissue samples. PHS-1 was
detected in all tissues. PHS-2 was not found in 23 of 25
normal colon tissues from cancer patients, but was found
in 19 of the 25 paired samples of cancers from these pa-
tients. PHS-2 protein was not detected in the four pre-
malignant polyps, the five control colon samples from
noncancer patients, or any of the samples of normal or
cancerous breast. In addition to the increased expression
of PHS-2 protein in 19 of 25 colon cancers, PHS-1 protein
was decreased in 21 of 25 colon cancers compared to nor-
mal colon (76). The evidence from the studies of Eberhart
(28) and Kargman (76) support the contention of abnormal
expression of PHS-2 as the source of the higher PGE2
levels found in some human colon cancers.
Excised tumors and colonic biopsy specimens contain
several cell types; thus, the cellular origin of prostanoids
found in these samples is not certain. Premalignant or
transformed cobonocytes, stromab and vascular cells, tissue
macrophages, and infiltrating lymphocytes are all among
the cell types possibly responsible for prostanoid produc-
tion in tumors. It is unlikely that infiltrating lymphocytes
are the source of PG synthesis in tumors because the num-
ber of tumor infiltrating lymphocytes was shown to de-
crease in the more advanced tumors (77). Production of
PGE2 by these tumors was confirmed by finding a greater
than sevenfold increase in PGE2 in blood leaving the tu-
mor compared to blood entering it. The ratio of PG in
venous to arterial tumor blood flow showed a positive cor-
relation with tumor severity and a negative correlation to
the number of infiltrating lymphocytes.
Most of the basal colonic PG production in humans orig-
inates submucosally, in the muscularis (78). The same oc-
curs in rat colon, where colon muscle layers were found
to have 10-fold the PG synthetic capacity of the mucosa.
The major PG synthesized in rat colon is PG!2 (79). As
these results refer to basal PG synthesis in nontumor tis-
sue, it is likely that PHS-1 is the isozyme responsible. The
occurrence of mRNA for PHS-1 in human (and rat) normal
and tumor colon has been reported (75).
A more comprehensive survey of human tissues for
PHS-1 and PHS-2 mRNAs was reported earlier by O’Neill
and Ford-Hutchinson (74), who showed that most tissues
express at least some PHS-1 and PHS-2 message even
without stimulation. P/IS-i mRNA was relatively abun-
dant in prostate, with lower levels in uterus, small intes-
tine, mammary gland, stomach, and lung. Still lower levels
were reported for thymus, liver, kidney, testis, and pan-
creas. The brain had the lowest amount of PHS-i mRNA
of the tissues tested. For PHS-2 mRNA, the pattern dif-
fered only in that the lung joined the prostate as the tissues
in highest abundance. The tissue distribution study did
not include the colon or rectum, and the use of whole
tissue may obscure regional distribution within a tissue
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such as differential expression of mRNAs in different
areas of the brain, kidney, or intestinal tract.
In situ hybridization experiments by Kutchera et al. (80)
determined that PHS-2 was expressed in carcinomatous
epthelial cells of the colon, but not in normal colonic ep-
ithelial cells. In contrast, PHS-1 was expresse(l in both
normal and cancerous regions. Colon cancer cell lines in
culture also overexpressed PHS-2. Noncancerous human
epithelial cells in culture did not express PHS-2 until
stimulated with interleukin-1, which caused them to reach
PHS-2 levels equivalent to colon cancer cells.
Evidence in the preceding paragraphs indicates that ab-
normal production of PHS-2 occurs in many colon cancers.
Thus, it is a logical step to examine the effect of PHS-2
specific inhibition as prevention or therapy for these can-
cers. The PHS-2-specific inhibitor SC-58635 was com-
pared with the nonspecific inhibitor sulindac in the
azoxymethane-induced cobonic aberrant crypt foci assay
in rats. Treatment with SC58635 at 1500 ppm reduced the
number of aberrant crypt foci per rat by 40%, which was
about the same reduction as seen with sulindac at 320
ppm. SC58635 at 150 ppm was without effect. There were
no ulcerogenic side effects of the SC58635 treatments
(81). Whether this experiment indicates a role for specific
inhibitors of PHS-2 in colon cancer prevention is still an
open question.
EFFECTS OF INHIBITION OF
PROSTAGLANDIN H SYNTHASES ON CELLS
Evidence that PGs are generally increased in colon tumors
and that PHS-2 is overexpressed in these tumors strength-
ens the hypothesis that PGs synthesized by PHS-2 are
involved in colorectal carcinogenesis. Since the normal
regulatory control of PHS-2 expression is somehow lost in
the tumors, and inhibitors of P1-IS (the NSAIDs) appear to
cause regression of cobonic tumors, research into the ef-
fects of PHS and its inhibition on colonic cell proliferation
and death has been plentiful.
Colonocytes are programmed to proliferate, differenti-
ate, and die in the normal progression from the base of
colonic crypts to the surface of the lumen of normal colon.
The number of colonocytes depends on the rate of prolif-
eration and the rate of programmed cell death, apoptosis.
An abnormality in one or more of the programs can result
in neoplasia. Investigation of carcinogenic and anticarci-
nogenic mechanisms must consider both proliferation and
apoptosis of cells. Two cultured lines of human colon ad-
enocarcinomas, SW1116 and HT-29, were treated with
several eicosanoids and the proliferation rate, distribution
in the cell cycle, and percentage of cells in apoptosis were
measured (82). HT-29 cells showed increased prolifera-
tion in the presence of PGE2, its methyl ester, its dimethyl
derivative, and leukotriene B4. SW1 116 cells proliferated
with the above-mentioned eicosanoids as well as with PGI2
and PGF2. The distribution of cells in the cycle was not
affected by the eicosanoids tested. Likewise, the rate of
apoptosis was not altered. The stable derivative of PGE2,
dimethyl PGE2, was injected into normal mice and the rate
of cobonocyte proliferation was subsequently measured. A
3.6-fold stimulation of proliferation was found, but there
was no change in the cell cycle distribution from that of
control animals (82).
If exogenous PGE2 causes proliferation of cobonic ade-
nocarcinoma cells, what is the effect of lowering PGE2 by
inhibiting PG synthesis? The NSAID sulindac is a prodrug
that is metabolized to the active form, sulindac sulfide, by
bacteria in the intestine of intact animals. Sulindac and
its sulfide both reduced the rate of proliferation of cultured
HT-29 cells, caused them to accummulate in the G0/G1
phase of the cell cycle, and increased the rate of apoptosis
(83); sulindac sulfide was about sixfold as potent as sulin-
dac. It was demonstrated by analysis of the culture me-
dium that unmetabolized sulindac was indeed active in
this system. In this study, neither PHS activity nor levels
of PGs were determined. At the dosages used (0.1-1.2mM
for sulindac and 0.05-0.2 mM for sulindac sulfide), it is
expected that PHS would be inhibited and PG synthesis
blocked, but nothing in the experiment directly links pros-
taglandins to the action of sulindac or sulindac sulfide.
The authors suggest that the antineoplastic effect of sulin-
dac sulfide is due to the decrease in colonocyte prolifer-
ation and the increased rate of apoptosis.
Further work by Shiff et a!. (84) demonstrated that other
NSAIDs including aspirin, indomethacin, naproxen, and
piroxicam, at or above concentrations achievable in
plasma, all reduced proliferation and altered the mor-
phology of HT-29 cells. Cell cycle distribution was altered
by these drugs to increase the proportion in G0/G1 with a
reduction in S phase cells. Aspirin and indomethacin also
reduced the proportion in G2/M, but naproxen and pirox-
icam did not. All the NSAIDs tested, except aspirin, in-
duced apoptosis. This work shows that several NSAIDs
have similar, but not identical, effects on tumor cells.
Of course, the fact that NSAIDs have a common target,
namely PHSs, would suggest that any effect these drugs
have in common is mediated via activity against this target.
The work reviewed here showing a common property of
NSAIDs to decrease tumor cell proliferation, alter mor-
phology, cause cells to accumulate in Go/Gi, and increase
the rate of apoptosis tends to further substantiate the com-
mon target of the drugs. But is it possible that there is
more than one common target for these compounds? Could
NSAIDs inhibit colon cancer by a prostaglandin-indepen-
dent pathway? There is significant evidence accumulating
that certain NSAIDs may be general activators of apoptosis
independent of their ability (or inability) to inhibit PHS.
In 1980, DeMelbo et al. (85) reported that anti-inflam-
matory drugs arrested growth of rat hepatoma and human
fibroblast cultures in the G1 phase. The effect was revers-
ible in that washing out of the drugs was followed by re-
sumption of cell growth. However, there was a lack of
correlation between the ability of NSAIDs to inhibit cell
growth and their potency as inhibitors of prostaglandin
synthase. Mecbofenamic acid and indomethacin inhibited
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TABLE 2. Inhibition of AOM-induced tumors and PGE2 content (89)
Carcinogen
Treatment:
NSAID and dose
Tumors, %
of
control
PGE2 content.b
% of control
AOM None 100.0 100.0
AOM Piroxicam 0.015% 38.5 17.3
AOM Sulindac0.04% 26.5’ 40.3’
AOM Sulindacsulfone0.1% 45.0’ 105.4
AOM Sulindacsulfone 0.2% 21.5’ 78.6
Colon tumors/animal. “PGE2/mg protein. Significantly different
from nontreated group (P<0.05).
cell growth only at concentrations far exceeding those re-
quired to inhibit PG synthesis. Phenacetin and salicylic
acid, which do not inhibit PG synthesis, were cytostatic
whereas antipyrine and aminopyrine, which are weak in-
hibitors, were not cytostatic.
A second line of evidence separating the effects of
NSAIDs on cell growth from the effect on PG synthesis
was that when indomethacin was used to inhibit cell
growth, the inhibition could not be overcome by added PGs
or arachidonic acid. If inhibition of PG synthesis were the
mechanism of NSAID cytostasis, addition of PG would be
expected to overcome the inhibition. This was not the case;
in fact, higher concentrations of PG enhanced the cyto-
static effect of indomethacin (85).
As mentioned previously, sulindac is a prodrug that is
reversibly reduced (mainly by intestinal flora) to sulindac
sulfide, which is several-fold more active as an anti-in-
flammatory than sulindac. However, sulindac can also be
irreversibly oxidized to sulindac sulfone, which is devoid
of prostaglandin inhibitory activity (86). Recently, Thomp-
son et al. (87) demonstrated that although 100 .tM sulin-
dac sulfide inhibited purified PHS-1 and PHS-2 85% and
43%, respectively, sulindac sulfone was not inhibitory for
either enzyme at up to 1000 l.tM. To examine if sulindac
sulfone was active in anticarcinogenesis, rats were dosed
with 1-methyl-1-nitrosourea, a mammary carcinogen, and
fed a standard diet, diet plus sulindac sulfone (0.03%),
diet plus sulindac sulfone (0.06%), or diet plus sulindac
(0.06%). At 24 wk, the sulindac-fed rats had fewer mam-
mary cancers than the controls; sulindac-sulfone treated
rats (0.03% dose) also had fewer mammary cancers than
the controls. The group on the higher dose of the sulfone
(0.06%) had the lowest incidence, lowest mean number of
tumors per rat, and lowest tumor burden of the groups.
This experiment demonstrated that sulindac sulfone, al-
though devoid of antiprostaglandin synthase activity, is
able to reduce mammary tumor occurence in this animal
model, thus providing additional evidence for the diver-
gence of PHS inhibition and tumor prevention.
Sulindac sulfone was also shown to inhibit growth of HT-
29 cells and other tumor and normal cells. Treatment with
sulindac sulfone did not alter the distribution of cells in
the cycle or cause differentiation of the cells. Cell number
decreased dramatically in response to a major increase in
the rate of apoptosis. Sulindac sulfide was two- to fourfold
as effective as the sulfone in eliciting these responses (88).
The effect of the non-PHS inhibitor sulindac sulfone on
azoxymethane-induced colon cancer in the rat was dem-
onstrated by Alberts et al. (89). Two weeks after dosing
with azoxymethane, rats were left untreated or treated with
piroxicam (0.015%), sulindac (0.04%), or sulindac sulfone
(0.10 or 0.20%) for 31 wk. Colonic neoplasms were re-
duced by all treatments, but colonic PGE2 content was
reduced only by piroxicam and sulindac (Table 2). What-
ever the mechanism of the antineoplastic effect of
NSAIDs, it does not necessarily include antiprostaglandin
activity.
Because a drug without anti-PG activity could suppress
tumor growth in cells that contain PG, what would be the
effect of NSAIDs on cells that do not synthesize PGs and
lack PHS, the putative target for NSAIDs? An interesting
experiment was carried out by Hanif et al. (90) with two
human colon adenocarcinoma cell lines, HT-29 (which
produces PGs) and HCT-15 (which does not produce PGs),
to determine the role of PGs in the inhibition of prolifer-
ation and induction of apoptosis by NSAIDs. Culture me-
dium from HCT-15 cells was devoid of PGs, whereas that
from HT-29 contained PGE2, PGF2, and PGI2. If the media
was supplemented with serum, HCT-15 cell media only
had the PG levels found in the serum, but HT-29 cells
had additional amounts of PGs above the serum levels.
Stimulation of PG synthesis by A23187, arachidonic acid,
and mellitin was unable to increase PG production by
HCT-15, but gave three- to fivefold increases in PG pro-
duction by HT-29 cells. Finally, RT-PCR failed to show
any mRNA for PHS-1 or PHS-2 in HCT-15, whereas the
messages were clearly seen in HT-29. Proliferation of
HCT-15 cells was only modestly affected by addition of
PGE2 or PGF2 (25% increase), but was severely reduced
by incubation with sulindac or piroxicam. Addition of PGs
along with sulindac or piroxicam did not reverse the
decrease in proliferation. Proliferation of HT-29 cells
was slightly increased by exogenous PGs, severely re-
duced by sulindac and piroxicam, and severely reduced
by addition of PGs with sulindac and piroxicam. Thus, in
the cultured cell lines, the NSAIDs sulindac and piroxi-
cam exerted their antiproliferative effect independent of
PG synthesis (90).
An interesting third line of evidence that the antipro-
liferative effect of NSAIDs on colon cells is independent
of PHS inhibition has recently been reported. The NSAIDs
ketoprofen, ketorolac, and flurbiprofen are 2-aryl-pro-
pionic acid derivatives that are chiral compounds and can
exist in the two enantiomeric forms R and S. The stereo-
specific inhibition of PHS-2 by these three NSAIDs was
assessed in guinea pig whole blood, LPS-stimulated hu-
man monocytes, and purified sheep placental enzyme
(PHS-2). Parallel models for PHS-i, similarly tested, were
clotting guinea pig blood, human polymorphonuclear cells,
and enzyme purified from ram seminal vesicles (PHS-1).
In all systems the S-enantiomers were far more inhibitory
than the R-enantiomers. The differences in IC50 values of
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S- vs. R-forms were as much as 500-fold. In fact, the small
inhibitory activity of the R-form could be accounted for by
very minor contamination by the S-form (<0.5%) (91).
The 5- and R-enantiomers of flurbiprofen were tested
for an antiproliferative effect on normal rat colonocytes in
vivo. After 30 days of flurbiprofen treatment, the animals
were given bromodeoxy-uridine, killed, and the stomach
and bowel were examined for ulceration and colonocyte
whole crypt labeling. The mean area of ulceration in the
small bowel of the rats given S-flurbiprofen was 20-fold
that of the rats given the R-form. The bromodeoxy-uridine
labeling index of colonocytes, which indicates cells in S-
phase, was 12.6% for control, 8.3% for R-flurbiprofen, and
9.7% for S-flurbiprofen (92). These results indicate that
even though PHS-1 and PHS-2 inhibition is stereoselec-
tive, with the S-enantiomer being the active form, the sup-
pression of cell proliferation by the R-enenatiomer is not
related to PHS-1 or PHS-2 isoenzymes and cell quies-
cence is an achiral process. The next step would be to test
the effects of R- and S-enantiomers in an experimental
carcinogenesis model rather than in normal rat intestine.
It would also be useful to try the enantiomers in a trans-
formed cell line, such as HCT-15, that does not produce
either PHS enzyme. The possibility that R-enantiomers of
certain NSAIDs are anticarcinogenic, nonulcerogenic, and
do not interfere with normal PG production could be an
important advance in the treatment or prevention of colon
cancer.
If NSAIDs exert their antiproliferative effects by non-
PG-dependent mechanisms, what are some of the possi-
bilities for the mechanisms of their actions? Abramson and
Weissmann (93) have reviewed some of the possibilities.
A number of biological processes other than PG synthesis
are inhibited by NSAIDs, although some of the effects re-
ported were observed at dosages several-fold above those
obtainable in vivo and therefore may not be biologically
relevant. Most NSAIDs are planar, anionic molecules that
partition into lipid bilayers of plasma membranes; the
more acidic the pH (as is found at inflammatory sites), the
greater the lipophilicity; thus, it is expected that they
would inhibit various membrane processes. Among the
membrane-associated enzyme activities inhibited by
NSAIDs are superoxide anion generation by NADPH
oxidase, phopholipase C activity, and 12-HPETE peroxi-
dase activity. Many NSAIDs interfere with uptake of ar-
achidonic acid and its insertion into membranes and also
interfere with anion transport across a variety of cell mem-
branes. NSAIDs have also been shown to uncouple oxi-
dative phosphorylation in mitochondria. The effects of
NSAIDs listed above are independent of their ability to
prevent synthesis of PGs; in fact, PGs and NSAIDs dem-
onstrate similar effects on several of the processes men-
tioned.
Another common property of NSAIDs and related drugs
that may explain their antineoplastic effect on colorectal
cancer is their ability to induce apoptosis of colonocytes.
The progressive genetic damage involving activation of on-
cogenes and loss of tumor suppressor genes as benign ad-
enomas undergo transition to malignant adenocarcinomas
has been we!! documented (94). It has also been recog-
nized that the size of the continuously renewing cell pop-
ulation of the gastrointestinal tract depends on both cell
proliferation and cell death via apoptosis. It has been
found that at each of four histopathological stages of neo-
plastic transformation, there is a progressive inhibition of
apoptosis. At 8 h of culture, the rate of apoptosis for normal
colonocytes was 60% but for carcinoma-derived cells the
rate was only 10%. Similar differences were observed at
24 h (85% and 30%, respectively). Apoptotic rates for
nonadenomatous polyps, FAP adenomas, and sporadic ad-
enomas were between normal and carcinoma values (95).
Histochemical staining for expression of bcl-2, which pro-
longs cell survival by inhibiting apoptosis, showed ex-
pression that was restricted to the proliferative zone at the
base and lower third of the crypt-epithelial column in nor-
mal tissue. In the colorectal carcinomas, in contrast, bcl-
2 protein was observed throughout the malignant
epithelium with no topographic restriction (89).
Additional recent reports have demonstrated that
NSAIDs induce apoptosis in colon carcinoma cells. Piazza
(88) reported that sulindac sulfide as well as sulindac sul-
fone, the metabolite lacking anti-PHS activity, induced
apoptosis in HT-29 cells and several other normal and
transformed cell lines from breast, melanoma, lung, and
kidney. Sulindac sulfide was three- to fourfold as potent
as the sulfone. Apoptosis rather than inhibition of cell pro-
liferation, altered differentiation, or necrotic cell death
was shown to be the mechanism for growth inhibition of
cells by sulindac sulfide and sulfone.
Shiff and colleagues (83) also demonstrated the induc-
tion of apoptosis in HT-29 cells by sulindac and sulindac
sulfide in a dose- and time-dependent manner that was
reversible by washing out the drugs. The examination was
subsequently extended to include aspirin, indomethacin,
naproxen, and piroxicam (84). All four drugs reduced the
proliferation and altered cell morphology of HT-29 cells
in a dose- and time-dependent manner. The NSAIDs, ex-
cept aspirin, induced apoptosis in this model.
Examination of the effect of sulindac on apoptosis in hu-
man FAP was conducted by Pasricha et al. (96). Twenty two
patients with FAP were treated with sulindac for 9 months.
At 3 and 6 months, there was a significant reduction in size
and number of polyps in the treated group. No change was
found in staining for proliferating cell nuclear antigen or
distribution in the cell cycle. However, the mean apoptotic
epithelial fraction was threefold higher after sulindac treat-
ment: 31 vs. 10% (P = 0.01). The effect of sulindac in
increasing apoptosis seen with colon carcinoma cell lines
also occurred with adenomatous polyps in vivo.
EFFECT OF PROSTAGLANDIN H SYNTHASE
OVEREXPRESSION ON INTESTINAL
EPITHELIAL CELLS
The effect of NSAIDs that inhibit PHS is induction of apo-
ptosis and regression of carcinoma and adenomatous pol-
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yps. Overexpression of PHS would be expected to have the
opposite effect and inhibit apoptosis and promote neopla-
sia. Tsujii and DuBois (97) tested this hypothesis by per-
manently transfecting rat intestinal epithelial cells
(RIE-P) with a PHS-2 expression vector oriented in the
sense direction (RIE-S) or, as a control, the anti-sense
direction (RIE-AS). They found elevated PHS-2 protein
expression and increased PG production, which was in-
hibited by sulindac sulfide in the RIE-S cells. Apoptosis
was inhibited in the RIE-S cells, and sodium butyrate
failed to induce apoptosis in these cells. Sulindac sulfide
overcame this inhibition in a dose-dependent manner in
the PHS-2 overexpressing cells.
Other changes in RIE-S cells included increased ad-
hesion and a reduction in apoptosis after butyrate treat-
ment. Sixfold more RIE-S cells attached to laminin- or
Matrigel-coated plates than did RIE-AS or nontransfected
RIE-P cells. All three lines attached equally to fibronec-
tin-coated plates. Cells expressing PHS-2 were able to at-
tach to Matrigel and survive on it, whereas cells without
detectable PHS-2 were unable to do so. PHS-2 expression
affected extracellular adhesion and survival. Apoptosis in
RIE cells plated on extracellular matrix was measured
with and without sodium butyrate treatment. Cells express-
ing PHS-2 were relatively resistant to apoptosis in both
cases. Sulindac sulfide eliminated the resistance in a dose-
dependent manner. PHS-2 overexpression also inhibited
cellular differentiation, as measured by alkaline phospha-
tase levels both with and without sodium butyrate treat-
ment. Sulindac sulfide overcame the block in cellular
differentiation and led to production of alkaline phospha-
tase in the PHS-2 expressing cells.
Overexpression of PHS-2 was accompanied by in-
creased levels of bcl-2, reduced TGF2 receptor protein
levels, and absence of E-cadherin protein. All of these
changes in RIE-S cells are in the direction of increased
cell survival and increased tumorigenic potential. These
results, taken together with the abnormal expression of
PHS-2 in many human colon tumors, support the inhibi-
tion of PHS-2 by NSAIDs as the antineoplastic mechanism
of this class of drugs (97). This hypothesis does not nec-
essarily involve formation of PGs as the signal molecules
inducing these tumorigenic effects.
If, as indicated, PHS-2 overexpression is associated
with colon tumor formation and survival, what causes
PHS-2 overexpression in vivo? The promoter region of
PHS-2 contains numerous recognition elements that
enable the gene to be activated by growth factors, cytoki-
nes, and tumor promoters (98, 99). PHS-2 expression may
even be controlled by TCDD and other halogenated hy-
drocarbons (100, 101). Any of several malignant transfor-
mations in a cell causing abnormal expression of a growth
factor could, in theory, lead to abnormal overexpression of
PHS-2. The expression of PHS-2 in colon cancer com-
pared to normal tissue was examined by Kutchera et a!.
(80), who compared PHS-2 expression in colon cancer and
normal tissue from the same patients. All the tumor sam-
ples had increased PHS-2 expression. In situ hybridization
confirmed that carcinomatous epithelial cells, but not the
normal epithelial cells, expressed PHS-2. Low levels of
PHS-1 were found in all cells.
Four colon cancer cell lines were examined for PHS-2
expression. All had constitutive expression of PHS-2. To
test for increased transcription, a reporter gene was con-
structed consisting of a 2 kb fragment of the human PHS-
2 promoter ligated to luciferase. Transfection of the
reporter construct into HCT-116 colon carcinoma cells
showed extensive luciferase activity without a need for in-
ducers. Transfection without the PHS-2 promoter did not
show activity, and transfection with the promoter into non-
cancerous cells required additional induction to show ac-
tivity. These experiments suggest that some factor
overexpressed in carcinoma cells leads to up-regulation of
the PHS-2 promoter (82). The up-regulation of PHS-2 may,
in turn, produce the increased cell survival and tumori-
genic potential reported by Tsujii and DuBois (97).
EFFECTS OF NSAIDS ON TUMOR
SUPPRESSOR AND CELL CYCLE
REGULATORY PROTEINS
Bcl-2 is an oncogene that acts specifically by blocking
apoptotic cell death. Expression of the bcl-2 protein has
been reported in solid tumors as well as hemopoietic
malignancies. Bcl-2 is differentially expressed in co-
lonic crypts, suggesting a role for it in the regulation of
colonic epithelium and possibly colorectal carcinogen-
esis. Hague et a!. (102) examined human colorectal ad-
enomas and carcinomas for bcl-2 expression and found
aberrant expression in adenocarcinomas, adenomas, ad-
enoma and carcinoma cell lines, and regional lymph
node metastesis of colon carcinoma. The findings of ab-
normal expression of the blc-2 gene is reminiscent of the
abnormal expression of PHS-2 in many colorectal car-
cinomas described by Eberhart (28), Kargman (76), and
Sano et al. (103) in humans and by Williams et a!. (104)
in Mm mouse adenomas.
Work with the cultured cell line HT-29, which is de-
rived from a moderately well-differentiated human colon
adenocarcinoma, has identified several proteins that play
a role in cell cycle progression and are affected by
NSAIDs. Shiff et al. (84) found a marked reduction in
levels of p33&2 and 34rsk2 after indomethacin or aspirin
treatment of HT-29 cells. These cyclin-dependent kinases,
together with cyclins, are essential for progression through
the eukaryotic cell cycle (105). The decrease in p33 and
p34 caused by NSAIDs parallels the accumulation of cells
in Go/G1 and the decrease in cells in S phase and G2/M.
Reduction in active cyclin-dependent kinases, leading to
a halt in cell cycle progression, may be responsible for
increased apoptosis and thus the antineoplastic action of
NSAIDs.
Sulindac and sulindac sulfide prevent HT-29 cells from
progressing from Go/G1 to S phase. The cell cycle block is
associated with an initial rise, then fall, in p34’2 protein
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(106). The regulatory units of the cdk’s also decrease in
response to sulindac: cyclins A and Bi were significantly
reduced. These results suggest that sulindac and its sulfide
induce a global decrease in the proteins of the cell cycle
molecular engine. The content of other proteins was also
changed by sulindac treatment. which can ar-
rest cell division by blocking the kinase activity of cdk’s,
was increased by sulindac. pRB, the retinoblastoma tumor
suppressor protein, exists in HT-29 cells in phosphory-
lated and underphosphorylated forms. Both forms of pRB
were reduced by sulindac. HT-29 cells contain a mutated
p53 tumor suppressor gene. Sulindac treatment reduces
the levels of mutated p53. In summary, Goldberg et al.
(106) found that the G1JG1 block induced by sulindac and
sulindac sulfide in HT-29 cells is associated with an initial
rise, followed by an abrupt decrease in p342, reduction
of mitotic cyclins, an increase in p2i1, a reduction
pRB with a relative increase in underphosphorylated pRB,
and a reduction in mutant p53. These responses are not
associated with cell differentiation and not strictly asso-
ciated with apoptosis. However, they may be the basis for
the anticarcinogenic activity of NSAIDs.
SUMMARY: MECHANISMS OF THE
ANTINEOPLASTIC EFFECTS OF NSAIDs
How NSAIDs prevent tumors and cause regression of co-
lorectal adenomas and adenocarcinomas is not known. As
is common in complex biological systems, there is prob-
ably more than one process affected by NSAIDs, and the
mechanism of action of individual NSAIDs may differ
slightly or significantly. In vitro it has been shown that
several NSAIDs can prevent carcinogen-DNA adduct for-
mation, an early step in tumor initiation. Studies of ex-
perimental carcinogenesis in animals have also shown that
NSAIDs can prevent chemical carcinogenesis and also re-
verse tumor formation when the drugs are administered
simultaneously with, or even weeks after, carcinogen ex-
posure. Clinical studies have demonstrated reduction in
polyps and adenomas in patients with familial adenoma-
tous polyposis as well as decreased progression to ade-
nocarcinomas in these patients. Epidemiologic studies
have clearly demonstrated greatly lowered incidence and
also mortality from colorectal cancers in users of NSAIDs.
No single mechanism has yet been shown to account for
all of these findings.
Evidence exists for the activity of PHS isozymes in the
activation of carcinogens to DNA damaging metabolites.
NSAIDs inhibit this activation. Several NSAIDs induce
apoptosis in colon epithelial cells, which seems to over-
come the inhibition of apoptosis that occurs in colorectal
cancer. A return to the normal rate of cell death would
certainly support tumor regression. The induction of apo-
ptosis appears to be independent of prostaglandin syn-
thase activity, as this effect of NSAIDs has been
demonstrated in cells devoid of PHS isozymes (93).
NSAIDs mediate several changes in cell cycle regulation.
Some of these effects on tumor suppressor genes, cyclins,
and cyclin kinases have been mentioned. There are un-
doubtedly many other factors in normal and malignant cell
regulation that are influenced by NSAIDs. Again, differ-
ences in the actions of the various NSAIDs are possible.
For example, aspirin and salicylate, but not indomethacin,
were found to inhibit activation of the transcription factor
NF-B, which is critical for the expression of multiple cel-
lular genes involved in inflammation, immunity, and ad-
hesion (107). Of particular interest to arachidonic acid
metabolism, the human arachidonate 12-lipoxygenase
gene has a negative regulatory region containing the NF-
B motif (108). Thus, it is conceivable that salicyclates may
inhibit NF-B, resulting in inhibition of various cellular
enzymes and factors and the loss of negative control of 12-
lipoxygenase. This would probably divert greater than nor-
mal amounts of arachidonic acid into the lipoxygenase
pathway at the expense of the prostaglandin H synthase
pathway. PHS-2 also has an NF-B regulatory motif that
may serve to increase transcription of the gene (98). In-
hibition of activation by salicyclates may result in lower
than normal levels of PHS-2.
NSAIDs as a class have targets other than prostaglandin
H synthases. Inhibition of NADPH oxidase, phospholipase
C, and 12-HPETE peroxidase as well as disruption of ar-
achidonic acid uptake and insertion into membranes, in-
terference with transmembrane anion transport, and
uncoupling of mitochondrial oxidative phosphorylation
have all been mentioned as common effects of NSAIDs
(93), although the biological importance of these effects is
unclear. It would be of great interest to test whether
NSAID-like drugs that are inactive in PHS inhibition but
have antineoplastic activity (sulindac sulfone) share the
above properties. Similarly, PHS-2 specific inhibitors
need to be tested for both antineoplastic activity and in-
hibition of membrane-associated enzyme activities.
There are still some prostaglandin H synthase-depen-
dent mechanisms that need additional consideration as
factors in the antineoplastic action of NSAIDs. When
PHS-2 is acetylated by aspirin, PG production decreases
markedly, but a new product, 15(R)-HETE, is produced
(47-49). The biological activity of this compound is
largely unknown. Additional compounds of the class of
15R-epimers of lipoxins are produced when HUVEC and
neutrophils are coincubated with aspirin but not indo-
methacin, salicylate, or dexamethasone. It is thought these
compounds, which are bioactive in the nanomolar range,
are produced by the interaction of acetylated PHS-2 and
5-lipoxygenase (109). There may be other compounds pro-
duced by NSAID treatment of arachidonate metabolizing
enzymes that remain undiscovered and could have impor-
tant effects on cell growth and death.
Clinical and experimental evidence that NSAIDs are an-
ticarcinogenic is strong, and recent studies have suggested
PHS-independent mechanisms for this action. The exact
relationship of PHS inhibition by NSAIDs to tumor pre-
vention remains uncertain. Whether or not PHS, as the
common target of NSAIDs, is involved in the protective
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effect of these drugs, the drugs and newer members of this
class, particularly PHS-2-specific inhibitors (81) and spe-
cific enantiomers of chiral NSAIDs (91, 92), should be
examined further as preventive and possibly curative
agents for colon and rectal cancers.
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